Oral small molecule GLP-1 receptor agonist
Loti po
LOTI_PO
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.41 (-10.74 to 1.76) | 0.81 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.78 (0.60 to 6.94) | 0.25 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.70 (2.50 to 14.14) | 0.12 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.61 (3.06 to 14.62) | 0.12 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.30 (3.14 to 23.51) | 0.14 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.27 (1.25 to 4.32) | 0.28 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.93 (2.48 to 10.76) | 0.09 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.62 (0.04 to 9.86) | 0.47 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.41 (-10.68 to 2.28) | 0.38 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.94 (0.58 to 8.02) | 0.38 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.82 (2.14 to 16.78) | 0.21 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.35 (4.71 to 14.89) | 0.15 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 13.00 (4.68 to 37.10) | 0.20 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.10 (1.03 to 4.47) | 0.46 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.42 (1.93 to 10.58) | 0.19 |